ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 586,40
-0,61%
Dow Jones
40 211,72
0,53%
DAX
18 514,21
-0,46%
Brent Oil
83,655
-0,81%
Bitcoin
63 268,34
-2,44%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateHeureSourceTitreSymboleSociété
23/05/201613h00GlobeNewswire Inc.Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM...NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:SMMTSummit Therapeutics Inc
12/05/201612h06Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:SMMTSummit Therapeutics Inc
10/05/201623h55Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:SMMTSummit Therapeutics Inc
10/05/201613h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
06/05/201613h00GlobeNewswire Inc.Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016NASDAQ:SMMTSummit Therapeutics Inc
28/04/201617h46GlobeNewswire Inc.Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid (SMT C1100), Into the...NASDAQ:SMMTSummit Therapeutics Inc
28/04/201613h00GlobeNewswire Inc.Summit Announces Further US Patent Granted for CDI Antibiotic RidinilazoleNASDAQ:SMMTSummit Therapeutics Inc
11/04/201613h00GlobeNewswire Inc.Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infe...NASDAQ:SMMTSummit Therapeutics Inc
06/04/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 15th Annual Needham Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
30/03/201613h00GlobeNewswire Inc.Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients W...NASDAQ:SMMTSummit Therapeutics Inc
29/03/201615h25GlobeNewswire Inc.Summit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin ...NASDAQ:SMMTSummit Therapeutics Inc
15/03/201612h00GlobeNewswire Inc.Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMDNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 TrialNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Therapeutics Supports Ninth Annual Rare Disease DayNASDAQ:SMMTSummit Therapeutics Inc
10/03/201601h46GlobeNewswire Inc.Summit Therapeutics Announces Publication of Preclinical Data Showing Ridinilazole Outperformed Standard of Care in Reducing ...NASDAQ:SMMTSummit Therapeutics Inc
17/02/201613h00GlobeNewswire Inc.Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug DayNASDAQ:SMMTSummit Therapeutics Inc
16/02/201619h20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SMMTSummit Therapeutics Inc
03/02/201613h00GlobeNewswire Inc.Summit Therapeutics to Present at 18th Annual BIO CEO & Investor ConferenceNASDAQ:SMMTSummit Therapeutics Inc
21/01/201613h00GlobeNewswire Inc.Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients ...NASDAQ:SMMTSummit Therapeutics Inc
19/01/201613h00GlobeNewswire Inc.Summit Therapeutics Granted Key European Patent for Novel Antibiotic Ridinilazole for Treatment of C. Difficile InfectionNASDAQ:SMMTSummit Therapeutics Inc
17/12/201513h00GlobeNewswire Inc.Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational ProgressNASDAQ:SMMTSummit Therapeutics Inc
14/12/201513h00GlobeNewswire Inc.Summit Therapeutics to Report Financial Results for the Third Quarter Ended 31 October 2015 on 17 December 2015NASDAQ:SMMTSummit Therapeutics Inc
10/12/201513h00GlobeNewswire Inc.Summit Therapeutics to Participate in the JMP Securities DMD ForumNASDAQ:SMMTSummit Therapeutics Inc
03/12/201513h00GlobeNewswire Inc.Summit Therapeutics to Present at the 26th Annual Oppenheimer Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
02/12/201513h00GlobeNewswire Inc.Summit Therapeutics Announces First Milestone Achieved in Strategic Alliance With University of Oxford for Future Generation ...NASDAQ:SMMTSummit Therapeutics Inc
25/11/201513h00GlobeNewswire Inc.Summit Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
23/11/201513h00GlobeNewswire Inc.Summit Therapeutics Announces Novel Antibiotic Ridinilazole (SMT19969) Achieves Statistical Superiority Over Vancomycin in Co...NASDAQ:SMMTSummit Therapeutics Inc
17/11/201513h00GlobeNewswire Inc.Summit Therapeutics and the University of Oxford Announce Multi-Year Extension of Strategic Alliance for Development of Utrop...NASDAQ:SMMTSummit Therapeutics Inc
30/09/201513h00GlobeNewswire Inc.Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMSNASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Dernières Valeurs Consultées

EU
AI
Air Liquide
NASDAQ
AAPL
Apple
EU
PX1
CAC 40
EU
VIV
Vivendi
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
EU
HO
Thales
EU
AF
Air FranceKLM
EU
PX4
SBF 120
EU
EN
Bouygues
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés